Table 1.

Current ocular disease authorized to be treated with anti-vascular endothelial growth factor (anti-VEGF) drugs by the National Institute for Clinical Excellence (NICE) and potential ocular diseases which are currently being studied

Disease	NICE-authorized anti-VEGF
Choroidal neovascularization secondary to age-related macular degeneration*	Ranibizumab, aflibercept
Macular oedema following central retinal vein occlusion*	Ranibizumab, aflibercept
Macular oedema following branch retinal vein occlusion*	Ranibizumab
Diabetic macula oedema*	Ranibizumab
Choroidal neovascularization secondary to pathological myopia*	Ranibizumab
Potential disease targets being studied
Polypoidal choroidopathy
Retinopathy of prematurity
Neovascular glaucoma
Sickle cell retinopathy
Proliferative diabetic retinopathy
Juxtafoveal telangectasia
Corneal neovascularization

^*UK licensed indications for ranibizumab and aflibercept. See http://www.ema.europa.eu/ for full European guidance.